ArticleAnnals of pediatric endocrinology & metabolism2022
Response to growth hormone according to provocation test results in idiopathic short stature and idiopathic growth hormone deficiency.
Article in Annals of pediatric endocrinology & metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- The impact of growth hormone therapy on ocular structural parameters in idiopathic short stature: a systematic review and meta-analysis.European journal of pediatrics · 2026Pooled it
- Interpretable Machine Learning for Predicting Suboptimal 12-Month Growth Response to Recombinant Human Growth Hormone in Children with Idiopathic Short Stature: A Dual-Center External Validation Study.Diagnostics (Basel, Switzerland) · 2026Article
- Predictors of Response to Growth Hormone Therapy in Children with Idiopathic Growth Hormone Deficiency: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Two-year real-world experience with somatrogon in children and adolescents with growth hormone deficiency.Frontiers in endocrinology · 2026Article
- Comparative Outcomes of GH Treatment in Pediatric Idiopathic Short Stature and GH Deficiency.Journal of the Endocrine Society · 2025Article
- Nutritional Counseling in Children with Growth Hormone Deficiency Treated with Recombinant Human Growth Hormone: Analysis of Growth Response Parameters.Biomedicines · 2025Article
- Article
- Development and Validation of a Prediction Model Using Sella Magnetic Resonance Imaging-Based Radiomics and Clinical Parameters for the Diagnosis of Growth Hormone Deficiency and Idiopathic Short Stature: Cross-Sectional, Multicenter Study.Journal of medical Internet research · 2024Article
- Article
- Response of children with Turner syndrome with different types of karyotype abnormalities to growth hormone treatment.Annals of pediatric endocrinology & metabolism · 2024Article
- A Radiomics-Based Model with the Potential to Differentiate Growth Hormone Deficiency and Idiopathic Short Stature on Sella MRI.Yonsei medical journal · 2022Article
- The effects of growth hormone treatment on height in short children.Annals of pediatric endocrinology & metabolism · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate growth response in children with either idiopathic short stature (ISS) or growth hormone (GH) deficiency (GHD).
methodsThe data of prepubertal GHD or ISS children treated using recombinant human GH were obtained from the LG Growth Study database. GHD children were further divided into partial and complete GHD groups. Growth response and factors predicting growth response after 1 and 2 years of GH treatment were investigated.
resultsThis study included 692 children (98 with ISS, 443 partial GHD, and 151 complete GHD). After 1 year, changes in height standard deviation score (ΔHt-SDS) were 0.78, 0.83, and 0.96 in ISS, partial GHD, and complete GHD, respectively. Height velocity (HV) was 8.72, 9.04, and 9.52 cm/yr in ISS, partial GHD, and complete GHD, respectively. ΔHt-SDS and HV did not differ among the 3 groups. Higher initial body mass index standard deviation score (BMI-SDS) and midparental height standard deviation score (MPH-SDS) were predictors for better growth response after 1 year in ISS and the partial GHD group, respectively. In the complete GHD group, higher Ht-SDS and BMI-SDS predicted better growth response after 1 year. After 2 years of GH treatment, higher BMI-SDS and MPH-SDS predicted a better growth outcome in the partial GHD group, and higher MPH-SDS was a predictor of good growth response in complete GHD.
conclusionClinical characteristics and growth response did not differ among groups. Predictors of growth response differed among the 3 groups, and even in the same group, a higher GH dose would be required when poor response is predicted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.